Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04279158

Attention Modulation of Local and Global Inhibition Mechanisms

Human behavior is both flexible and adapted to the environmental context through inhibition capabilities; the investigator control the subject's behavior by repressing inappropriate responses and selecting, among several possibilities, those that are appropriate. These mechanisms are not independent of attentional control. Attention acts as a selection filter for the investigator's behavior. This leads us to hypothesize that attention modulates the mechanisms of inhibition. Nevertheless, the different brain structures involved, as well as mechanisms underlying the interaction between inhibition and attention remain largely unknown.

Previous research has suggested that inhibition requires selective attention and, conversely, attentional mechanisms would result in the "deselection", or inhibition, of objects in space or irrelevant actions. Reconciling the literature on attention with the one on inhibition appears fundamental for the understanding of the instance to which the mechanisms of inhibition and the cognitive processes interact. Therefore, the goal of this research project will be to investigate how inhibition mechanisms are implemented in the brain and, in more detail, what determines the type of resulting inhibitory control: spatially localized or global. The investigator will test 3 different patient groups (optic ataxia, hemispatial neglect and attention-deficit hyperactivity disorder) compared to control.

In conclusion, this research project will aim to develop a theoretical model of the interaction between attentional control and inhibition mechanisms in order to improve diagnostic and rehabilitation tools in the future.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Optical Phenomena Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Behavior Inhibition, Psychological Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurodevelopmental Disorders Neurologic Manifestations Pathological Conditions, Signs and Symptoms Perceptual Disorders Signs and Symptoms

Age range

8 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de Recherche en Neuroscience de Lyon

Bron, 69500, France

Location status: Recruiting

Location contact

Julie OUERFELLI-ETHIER

CONTACT

[email protected]

laure PISELLA, PhD

CONTACT

[email protected]

4 72 91 34 05 ext. +33

laure PISELLA, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

All patients and healthy subjects:

Inclusion criteria

  • male and female, age from 18 to 75 years included
  • normal vision or corrected vision
  • covered by social security
  • signed written informed consent

Exclusion criteria

  • unable to comply with requirements of the study (neurological, psychiatric, sensory or motor troubles)
  • adults under legal protection

Patient with hemispatial neglect:

Inclusion criteria

  • After a stroke (> 1 month ago), presence of a neurological impairment documented by brain imaging (standard of care) and by clinical symptoms.
  • The diagnosis will be dissociated from hemianopia by perimetry. The hemispatial neglect consists of a lack of perception and responsiveness concerning the controlesional visual hemifield.

Patient with optic ataxia:

  • After a stroke (> 1 month ago), presence of neurological injury in parietal cortex only, supported by a standard of care cerebral MRI
  • Present optic ataxia symptoms (The OA consists of pointing errors with the hand contralateral to the lesion (hand effect) and / or to visual targets presented in the field contralateral to the lesion (field effect)).

Patient (adult and children) with attention-deficit hyperactivity disorder:

  • present a diagnosis of ADHD subtype inattention or impulse / hyperactivity as established by a neuropsychologist.
  • Children will be between 8 and 18 years old
  • Adults will be between 18 and 75 years old.
  • Participants will not report any comorbid learning disabilities to ADHD.

For minors:

  • Having obtained the written consent of the legal representative(s)

Healthy subjects

Inclusion criteria

  • no known neurological injury

Treatment and study plan

experience 1 "The negative priming task"

Behavioral

The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

experience 2 "Stop signal task"

Behavioral

The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target

experience 3 "Anti-saccades"

Behavioral

The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target

Primary outcomes

  1. error rate

    Time frame: at the end of the simulation passage, an average of 3 years

    The investigator calculate the number of right and wrong answers (a correct answer is a saccade carried out when it is necessary and by reaching the target; a false answer is a saccade made at the wrong time and / or not reaching the target) to obtain the error rate.

Secondary outcomes

  1. reaction time

    Time frame: at the end of the simulation passage, an average of 3 years

    The investigator measure the time it takes for the subject to respond (perform the eye saccade)

Study contacts

Contact information is provided by the study sponsor or research team.

Julie OUERFELLI-ETHIER

CONTACT

[email protected]

Laure PISELLA, PhD

CONTACT

[email protected]

4 72 91 34 05 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: MILGattention

Important dates

Study start
2022
Primary completion
2031
Study completion
2031
First posted
Feb 21, 2020
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.